Abstract 492P
Background
The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is a standard treatment in case of T790M mutation positive after failure to first or second generation EGFR TKI in patients with EGFR-mutant non-small cell lung cancer (NSCLC). We investigated a success rate of rebiopsy and sequential EGFR TKI treatment in real world setting in Korea.
Methods
We retrospectively reviewed medical records of patients with EGFR mutant advanced NSCLC who received first- or second- generation EGFR TKI between Jan 2012 and Jun 2018 at a single center in Korea.
Results
Among 221 patients with EGFR-mutant NSCLC, 68 patients who were lost to follow up (n = 19) or still on 1st- or 2nd- generation TKI (n = 49) at time of analysis were excluded. Forty-three out of remaining 153 patients (28%) did not have a chance of consideration for second line treatment because of deterioration of performance status (n = 21) or death (n = 22), especially in elderly over 70 years. Tests for acquired EGFR mutation were performed in 76% (84/110), among which 73 cases were tissue rebiopsy and 11 cases were plasma EGFR mutation analysis. Acquisition of tumor tissue in rebiopsy was successful in 93% (68/73). The most common reason of not doing rebiopsy was lack of sequential treatment options (n = 24). Ten patients with negative T790M or failure at initial rebiopsy underwent more than two times of repeated EGFR mutation analysis, among which four patients had eventually positive T790M at some point of disease course. Overall T790M positive rate was 54% (45/84). Among 7 patients with initially negative T790M mutation in plasma analysis, further rebiopsy from tumor tissue was performed only in one patients because of patient's refusal (n = 2), physician's decision to continue post-progression EGFR TKI (n = 2), poor performance status (n = 1), and unaccessibility to tumor tissue (n = 1).
Conclusions
About 30% of patients with EGFR mutant NSCLC did not have a chance of consideration for second line EGFR TKI treatment, especially in elderly over 70 years. Success rate of tumor tissue rebiopsy was over 90% in real world setting, and repeated rebiopsy may increase detection rate of acquired T790M mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract